A Study in Non-Small Cell Lung Cancer

Part of paid clinical trials in Monterey, California.

Sponsor
N-Power Medicine
Study ID
NCT07174388
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

A study to create control arms using current and future information in patients with lung cancer.

Key Dates

Start date
Jan 7, 2026
Status verified
May 2026
Primary completion
Apr 30, 2029
Completion
Apr 30, 2029

Study Design

Enrollment
550 participants (estimated)

Arms

  • Arm: Cohort 1
    Patients starting first line pembrolizumab or pembrolizumab in combination with a platinum doublet
  • Arm: Cohort 2
    Patients with KRASG12D mutation starting first or later line of therapy
  • Arm: Cohort 3
    Patients planned to have second line docetaxel or docetaxel in combination with ramucirumab with tumor without alterations in KRAS, EGFR, ALK, or ROS1
  • Arm: Cohort 4
    Patients with PD-L1 \> 50% treated with single agent immuno-oncology therapy (IO) or dual IO agents as first line treatment.
  • Arm: Cohort 5
    Patients with PD-L1 \< 50% without alterations in KRAS, EGFR, ALK, or ROS1
  • Arm: Cohort 6
    Patients with documented KRAS G12C mutation
  • Arm: Cohort 7
    Patients with non-G12C and non-G12D KRAS mutations
  • Arm: Cohort 8
    Patients with EGFR mutations with prior treatment with osimertinib in combination with chemotherapy or lazertinib in combination with amivantamab
  • Arm: Cohort 9
    Patients initiating single agent docetaxel or docetaxel and ramucirumab as third line of therapy

Primary Outcome Measure

Assess Objective Response Rate (ORR) by cohort in patients with metastatic NSCLC treated in second or third line with NCCN recommended therapies [ Time Frame: September 2025-April 2029 ]

Locations (8)

FacilityCityStateZIPSite coordinators
Pacific Cancer CareMontereyCalifornia93940
Alexander Baskoro
[email protected]
831-375-4105
Anushi Bulumulle, MD (PRINCIPAL_INVESTIGATOR)
Bayhealth Medical Center, Kent CampusDoverDelaware19901
Ruby Davis
[email protected]
302-744-7795
Iftekhar Khan, MD (PRINCIPAL_INVESTIGATOR)
Bayhealth Medical Center- Sussex CampusMilfordDelaware19963
Iftekhar Khan, MD (PRINCIPAL_INVESTIGATOR)
Northwest Oncology and HematologyBarringtonIllinois60010
Nowsheen Azeemuddin
[email protected]
847-577-0620
Roberto Montoya, MD (PRINCIPAL_INVESTIGATOR)
Northwest Oncology and HematologyElk GroveIllinois60008
Nowsheen Azeemuddin
[email protected]
847-577-0620
Roberto Montoya, MD (PRINCIPAL_INVESTIGATOR)
Northwest Oncology and HematologyHoffman EstatesIllinois60169
Nowsheen Azeemuddin
[email protected]
847-577-0620
Roberto Montoya, MD (PRINCIPAL_INVESTIGATOR)
Northwest Oncology and HematologyRolling MeadowsIllinois60008
Nowsheen Azeemuddin
[email protected]
847-577-0620
Roberto Montoya, MD (PRINCIPAL_INVESTIGATOR)
Oncology ConsultantsHoustonTexas77030
Research Office
[email protected]
713-600-0913
Luis Campos, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Monterey, CA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Pacific Cancer Care· Monterey, CABayhealth Medical Center, Kent Campus· Dover, DEBayhealth Medical Center- Sussex Campus· Milford, DENorthwest Oncology and Hematology· Barrington, ILNorthwest Oncology and Hematology· Elk Grove, ILNorthwest Oncology and Hematology· Hoffman Estates, IL

Related Studies